Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Blood

Volumn 118, Issue 20, 2011, Pages 5573-5582

  Deneberg, Stefan ^a   Guardiola, Philippe ^b,c   Lennartsson, Andreas ^d   Qu, Ying ^a   Gaidzik, Verena ^e   Blanchet, Odile ^b,c   Karimi, Mohsen ^a   Bengtzén, Sofia ^a   Nahi, Hareth ^a   Uggla, Bertil ^f   Tidefelt, Ulf ^f   Höglund, Martin ^g   Paul, Christer ^a   Ekwall, Karl ^d   Döhner, Konstanze ^e   Lehmann, Sören ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSERM   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MOLECULAR MARKER; NUCLEOPHOSMIN; POLYCOMB GROUP PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMATIN; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STEM CELL;

EID: 81555214615     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-332353     Document Type: Article

References (42)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
2. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu Rev Pathol. 2009;4:229-249.
3. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705. (Pubitemid 46273577)
4. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS. 2007;115(10):1039-1059. (Pubitemid 350179474)
5. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009;113(16):3666-3672.
6. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
7. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
8. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
10. Edvardsson L, Olofsson T. Real-time PCR analysis for blood cell lineage specific markers. Methods Mol Biol. 2009;496:313-322.
11. Fan JB, Gunderson KL, Bibikova M, et al. Illumina universal bead arrays. Methods Enzymol. 2006;410:57-73.
12. Deneberg S, Grovdal M, Karimi M, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia. 2010;24(5):932-941.
13. Karimi M, Johansson S, Stach D, et al. LUMA (LUminometric Methylation Assay): a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res. 2006;312(11):1989-1995. (Pubitemid 43850924)
14. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
15. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20(18):3705-3706. (Pubitemid 40136823)
16. Benjamini YHY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;B:289-300.
17. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002;18(1):207-208. (Pubitemid 34145055)
18. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376-392.
19. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev Genet. 2004;5(6):446-455. (Pubitemid 38915411)
20. Bjornsson HT, Sigurdsson MI, Fallin MD, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA. 2008; 299(24):2877-2883. (Pubitemid 351930887)
21. McGarvey KM, Van Neste L, Cope L, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res. 2008;68(14):5753-5759.
22. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157-158. (Pubitemid 46184343)
23. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009;9(11):773-784.
24. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125(2):315-326.
25. Cui K, Zang C, Roh TY, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell. 2009;4(1):80-93.
26. Adli M, Zhu J, Bernstein BE. Genome-wide chromatin maps derived from limited numbers of hematopoietic progenitors. Nat Methods. 2010;7(8):615-618.
27. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125(2):301-313. (Pubitemid 44313811)
28. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27.
29. Tan PT, Wei AH. The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. Pathology. 2011;43(6):536-546.
30. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339-344.
31. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
32. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood. 2010;116(25):5465-5475.
33. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39(2):232-236. (Pubitemid 46184355)
34. Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer. 2010;9:44.
35. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007;39(2):237-242.
36. Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci U S A. 2008;105(50):19809-19814.
37. He H, Hua X, Yan J. Epigenetic regulations in hematopoietic Hox code. Oncogene. 2011;30(4):379-388.
38. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833. (Pubitemid 350006257)
39. Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008;22(11):2041-2047.
40. Debernardi S, Lillington DM, Chaplin T, et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer. 2003;37(2):149-158. (Pubitemid 36529782)
41. Pillozzi S, Brizzi MF, Bernabei PA, et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-1250. (Pubitemid 47281422)
42. Agarwal JR, Griesinger F, Stuhmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010;9:18.